Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Surgery for high-risk prostate cancer is challenging but doesn't lead to more complications, and additional treatment is often needed.

No link found between hair loss severity and PSA levels in men.

This review discusses the expression of PSA in hormonally-regulated tissues and female malignancies, emphasizing its potential as a diagnostic biomarker and role in antidoping initiatives.

This study identified genetic variations in the DSG4 gene among sheep, revealing valuable markers for assessing their impact on wool traits.

In this case report, the researchers emphasize the importance of regular prostate exams and PSA tests for diabetic men, including those who are hypogonadal, because prostate cancer development is linked to intraprostatic dihydrotestosterone levels, not serum testosterone levels.

In this study, researchers investigated the effects of Aqueous Artocarpus heterophyllus seed extract on testosterone enanthate-induced benign prostatic hyperplasia in adult Wistar rats, using three different dosages to assess its potential as an alternative therapy. Results are not reported in this abstract.

This review discusses phytotherapy options for managing benign prostatic hyperplasia, noting some herbal agents show promise in trials for mild-moderate symptoms but more evidence is needed for others.

Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.

This review discusses the adverse effects of 5α-reductase inhibitors, finasteride and dutasteride, on sexual, psychological, and vascular health, emphasizing the need for physicians to inform patients of these risks.

This study observed a temporal association between tamsulosin use for benign prostatic hyperplasia and an increased risk of severe hypotension requiring hospital admission during the first eight weeks of treatment initiation and restart.

This study found that 5α-reductase inhibitors significantly increase the risk of erectile dysfunction and hypoactive sexual desire in men with benign prostatic hyperplasia, compared to placebo.

This study concluded that five-alpha-reductase inhibitors may reduce prostate cancer risk but could increase the risk of high-grade prostate cancer in men regularly screened for the disease.

This study found that 5-α reductase inhibitors do not significantly increase the risk of erectile dysfunction in men with benign prostatic hyperplasia or alopecia, although duration of benign prostatic hyperplasia may elevate risk.

This study observed that frontal plus moderate vertex baldness at age 45 was associated with a higher risk of aggressive prostate cancer in a large cohort.

This study suggests that the use of finasteride for benign prostate hyperplasia may increase the risk of osteoporosis diagnosis, particularly at higher doses.

This study observed that men receiving dutasteride for benign prostatic hyperplasia did not show significant differences in neuropsychological assessments compared to a control group not on dutasteride.

This review summarized existing research on finasteride and erectile dysfunction, finding a correlation between finasteride use for benign prostatic hyperplasia and ED, but not strongly for male androgenetic alopecia.

This study found that serum PSA levels are higher in hirsute women and can be significantly reduced by antiandrogen treatment, suggesting PSA as a marker of androgen action in females.

This study found that α-spinasterol treatment significantly reduced testosterone propionate-induced prostatic hyperplasia in rats, suggesting potential benefits for managing benign prostatic hyperplasia.

This study suggests that using both finasteride and dutasteride may increase the risk of acute coronary syndrome in patients with benign prostate hyperplasia.

In this study conducted at Sir Ganga Ram Teaching Hospital in Pakistan, researchers found that preoperative use of finasteride significantly reduced intraoperative blood loss and shortened hospital stay for benign prostatic hyperplasia patients undergoing bipolar TURP, compared to those not receiving finasteride.

In a rat model of benign prostatic hyperplasia, this study found that purple corn extract may improve symptoms by inhibiting prostate enlargement, reducing androgen receptor signaling, and exerting anti-inflammatory effects.

This literature review identified that phosphodiesterase 5 inhibitors, such as Tadalafil, are highly effective in improving lower urinary tract symptoms associated with benign prostatic hyperplasia, while the efficacy of saw palmetto remains inconsistent.

This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.

This study found that dutasteride is more cost-effective compared to finasteride for treating benign prostatic hyperplasia in Montenegro, justifying its funding by the national health insurance fund.

Certain gene variants may raise the risk of prostate enlargement, but taking NSAIDs could reduce this risk.

This review discusses the role of 5α-reductase in prostate development and BPH, and reports no new clinical results; ongoing trials are exploring dual isozyme inhibitors for improved treatment efficacy.

This review critically examines the current medical management strategies for BPH/LUTS and reports no new experimental results.

This study demonstrates that patients with benign prostatic hyperplasia have a higher severity and frequency of male pattern baldness compared to a control group.

This article reviews the effects of 5 alpha-reductase inhibitors for treating conditions like male pattern baldness and benign prostatic hyperplasia, noting significant DHT reduction but reports no new clinical results.